Tomohiro Watanabe
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Tomohiro Watanabe has a total of 25 co-authors. Here are the top co-authors by number of shared publications:
- Tomohiro Fujii
Ajinomoto (Japan)
4 shared publications - Yutaka Matsuda
Ajinomoto Co., Inc., 1-1 Suzuki-cho, Kawasaki, Kanagawa 210-8681, Japan
4 shared publications - Rika Takasugi
Ajinomoto (Japan)
3 shared publications - Takuya Seki
Ajinomoto (Japan)
3 shared publications - Yusuke Iwai
Ajinomoto (Japan)
3 shared publications - Akira Nakayama
Ajinomoto (Japan)
2 shared publications
Latest Publications
- Open Access
- 25 September 2023
- Published by American Chemical Society (ACS) in ChemRxiv
Exo-Cleavable Linkers: A Paradigm Shift for Enhanced Stability and Therapeutic Efficacy in Antibody-Drug Conjugates
Customized drug delivery systems have become paramount in the rapidly evolving field of precision medicine, and at the forefront of advances in this regard, antibody-drug conjugates (ADCs) present a symbiotic fusion of cytotoxic payloads and monoclonal antibodies (mAbs) facilitated by intricate chemical linkers. The search for ideal linkers that can dexterously provide the dual functionalities of enhancing circulatory stability and facilitating the effective release of the tumor payload is a present and formidable challenge. The valine-citrulline (Val-Cit) linker, which is used in a wide range of ADCs, despite its approval by the Food and Drug Administration, is associated with several inherent drawbacks, including hydrophobicity-induced aggregation, limited payload capacity, and premature payload release. This study presents a paradigm shift from the conventional linear linker archetype by introducing an exo-linker avant-garde approach that repositions the cleavable peptide linker at the exo-position of the PAB moiety. This molecular refinement not only offered the possibility to overcome the intrinsic drawbacks of the Val-Cit platform, but also significantly improved ADC stability, therapeutic efficacy, and pharmacokinetics. In vitro and in vivo biological evaluations, confirmed that ADCs designed using the exo-linker blueprint significantly attenuated premature payload release, while increasing the drug-to-antibody ratio, even with hydrophobic payloads, and this without inducing pronounced aggregation. Therefore, the fabricated exo-linker represents a significant improvement with respect to traditional Val-Cit ADCs. Moreover, under the influence of enzymes, such as carboxylesterases and human neutrophil elastase, the payload remained stably conjugated to the ADC, underscoring a favorable safety profile and highlighting potential for clinical translatability. Thus, our findings also demonstrate the potential of the novel exo-linker paradigm as well as the profound implications of nuanced molecular modifications for reshaping ADC design and functionality.
- 25 September 2023
- Published by American Chemical Society (ACS) in ChemRxiv
Open AccessExo-Cleavable Linkers: A Paradigm Shift for Enhanced Stability and Therapeutic Efficacy in Antibody-Drug Conjugates
Customized drug delivery systems have become paramount in the rapidly evolving field of precision medicine, and at the forefront of advances in this regard, antibody-drug conjugates (ADCs) present a symbiotic fusion of cytotoxic payloads and monoclonal antibodies (mAbs) facilitated by intricate chemical linkers. The search for ideal linkers that can dexterously provide the dual functionalities of enhancing circulatory stability and facilitating the effective release of the tumor payload is a present and formidable challenge. The valine-citrulline (Val-Cit) linker, which is used in a wide range of ADCs, despite its approval by the Food and Drug Administration, is associated with several inherent drawbacks, including hydrophobicity-induced aggregation, limited payload capacity, and premature payload release. This study presents a paradigm shift from the conventional linear linker archetype by introducing an exo-linker avant-garde approach that repositions the cleavable peptide linker at the exo-position of the PAB moiety. This molecular refinement not only offered the possibility to overcome the intrinsic drawbacks of the Val-Cit platform, but also significantly improved ADC stability, therapeutic efficacy, and pharmacokinetics. In vitro and in vivo biological evaluations, confirmed that ADCs designed using the exo-linker blueprint significantly attenuated premature payload release, while increasing the drug-to-antibody ratio, even with hydrophobic payloads, and this without inducing pronounced aggregation. Therefore, the fabricated exo-linker represents a significant improvement with respect to traditional Val-Cit ADCs. Moreover, under the influence of enzymes, such as carboxylesterases and human neutrophil elastase, the payload remained stably conjugated to the ADC, underscoring a favorable safety profile and highlighting potential for clinical translatability. Thus, our findings also demonstrate the potential of the novel exo-linker paradigm as well as the profound implications of nuanced molecular modifications for reshaping ADC design and functionality.
- Open Access
- 25 August 2023
- Published by American Chemical Society (ACS) in ChemRxiv
Bispecific Antibodies Produced via Chemical Site-Specific Conjugation Technology: AJICAP Second Generation
Bispecific antibodies are biotherapeutics that amalgamate the specificities of two distinct antibodies into one molecule. Bispecific antibodies can be utilized in a broad range of diagnostic and therapeutic applications; however, their engineering requires genetic modification and remains time-consuming. Therefore, in this study, we used AJICAP second-generation technology, which drives the production of site-specific antibody-drug conjugates in a practical and robust manner, without genetic modification requirements, to generate bispecific antibodies. Using haloketone chemistry as an alternative to maleimide chemistry, which carries reaction risks, we successfully produced site-specific antibody conjugates. Pharmacokinetic studies revealed that the haloketone-based antibody conjugate was stable in the rat plasma. The resultant bispecific antibodies were rigorously evaluated, and surface plasmon resonance measurements and flow cytometry analyses confirmed that antigen binding remained intact. Additionally, the affinity for the neonatal Fc receptor (FcRn) was retained after conjugation. Further cytotoxicity evaluation emphasized the pronounced activity of the generated bi-specific antibodies. These preliminary findings highlight the potential of AJICAP second-generation technology in BisAb production. This novel approach introduces a fully chemical, site-specific strategy capable of producing bispecific antibodies, heralding a new era in the field of biotherapeutics.
- 25 August 2023
- Published by American Chemical Society (ACS) in ChemRxiv
Open AccessBispecific Antibodies Produced via Chemical Site-Specific Conjugation Technology: AJICAP Second Generation
Bispecific antibodies are biotherapeutics that amalgamate the specificities of two distinct antibodies into one molecule. Bispecific antibodies can be utilized in a broad range of diagnostic and therapeutic applications; however, their engineering requires genetic modification and remains time-consuming. Therefore, in this study, we used AJICAP second-generation technology, which drives the production of site-specific antibody-drug conjugates in a practical and robust manner, without genetic modification requirements, to generate bispecific antibodies. Using haloketone chemistry as an alternative to maleimide chemistry, which carries reaction risks, we successfully produced site-specific antibody conjugates. Pharmacokinetic studies revealed that the haloketone-based antibody conjugate was stable in the rat plasma. The resultant bispecific antibodies were rigorously evaluated, and surface plasmon resonance measurements and flow cytometry analyses confirmed that antigen binding remained intact. Additionally, the affinity for the neonatal Fc receptor (FcRn) was retained after conjugation. Further cytotoxicity evaluation emphasized the pronounced activity of the generated bi-specific antibodies. These preliminary findings highlight the potential of AJICAP second-generation technology in BisAb production. This novel approach introduces a fully chemical, site-specific strategy capable of producing bispecific antibodies, heralding a new era in the field of biotherapeutics.
- Open Access
- 5 April 2023
- Published by American Chemical Society (ACS) in ChemRxiv
Gram-Scale Synthesis of Site-Specific Antibody-Drug Conjugates Using AJICAP Second-Generation Technology
Chemical site-specific conjugation technology utilizing immunoglobulin-G (IgG) Fc-affinity reagents is a versatile and promising tool for producing next-generation antibody-drug conjugates (ADCs). Our research group recently reported a novel Fc-affinity peptide-mediated conjugation method, termed AJICAP second-generation. This technology, based on thioester chemistry, produces site-specific ADCs without aggregation. Herein, we report further investigations into the AJICAP second-generation technology. By varying the parameters of the peptide conjugation step, it was found that this reaction is feasible under a wide range of reaction conditions. All synthetic intermediates of the AJICAP-ADCs were sufficiently stable, indicating that each synthetic step is a possible holding point in ADC manufacturing. The Lys248- and Lys288-conjugated ADCs were prepared on a gram-scale using two different Fc-affinity peptide reagents, employing a scale-down manufacturing approach involving tangential flow filtration (TFF). The total product yield was > 80%, and ultimately, 13.2 g of trastuzumab-Lys248-MMAE and 1.26 g of trastuzumab-Lys288-MMAE were obtained with high drug to antibody ratios (DARs). The results strongly indicate that the AJICAP second-generation method is a robust and practical approach for the manufacture of ADCs.
- 5 April 2023
- Published by American Chemical Society (ACS) in ChemRxiv
Open AccessGram-Scale Synthesis of Site-Specific Antibody-Drug Conjugates Using AJICAP Second-Generation Technology
Chemical site-specific conjugation technology utilizing immunoglobulin-G (IgG) Fc-affinity reagents is a versatile and promising tool for producing next-generation antibody-drug conjugates (ADCs). Our research group recently reported a novel Fc-affinity peptide-mediated conjugation method, termed AJICAP second-generation. This technology, based on thioester chemistry, produces site-specific ADCs without aggregation. Herein, we report further investigations into the AJICAP second-generation technology. By varying the parameters of the peptide conjugation step, it was found that this reaction is feasible under a wide range of reaction conditions. All synthetic intermediates of the AJICAP-ADCs were sufficiently stable, indicating that each synthetic step is a possible holding point in ADC manufacturing. The Lys248- and Lys288-conjugated ADCs were prepared on a gram-scale using two different Fc-affinity peptide reagents, employing a scale-down manufacturing approach involving tangential flow filtration (TFF). The total product yield was > 80%, and ultimately, 13.2 g of trastuzumab-Lys248-MMAE and 1.26 g of trastuzumab-Lys288-MMAE were obtained with high drug to antibody ratios (DARs). The results strongly indicate that the AJICAP second-generation method is a robust and practical approach for the manufacture of ADCs.
- Open Access
- 30 January 2023
- Published by American Chemical Society (ACS) in ChemRxiv
AJICAP Second Generation: Improved Chemical Site-Specific Conjugation Technology for Antibody-Drug Conjugate Production
The site-directed chemical conjugation of antibodies remains an area of great interest and active efforts within the antibody-drug conjugate (ADC) community. We previously reported a unique site modification using a class of immunoglobulin-G (IgG) Fc-affinity reagents to establish a versatile, streamlined, and site-selective conjugation of native antibodies to enhance the therapeutic index of the resultant ADCs. This methodology, termed “AJICAP,” successfully modified Lys248 of native antibodies to produce site-specific ADC with a wider therapeutic index than the Food and Drug Administration-approved ADC, Kadcyla. However, the long reaction sequences, including the reduction-oxidation (redox) treatment, increased. In this manuscript, we aimed to present an updated Fc-affinity-mediated site-specific conjugation technology named “AJICAP second generation” without redox treatment utilizing a "one-pot” antibody modification reaction. The stability of Fc affinity reagents was improved owing to structural optimization, enabling the production of various ADCs without aggregation. In addition to Lys248 conjugation, Lys288 conjugated ADCs with homogenous drug-to-antibody ratio of 2 were produced using this technology after a proper modification of the spacer linkage of Fc-affinity peptide reagents. These two conjugation technologies were used to produce over 20 ADCs from several combinations of antibodies and drug linkers. The in vivo profile of Lys248 and Lys288 conjugated ADCs was also compared. Furthermore, non-traditional ADC applications, such as antibody-protein conjugates and antibody-oligonucleotide conjugates, were performed. These results strongly indicate that this Fc affinity conjugation approach is a promising strategy for manufacturing site-specific antibody conjugates.
- 30 January 2023
- Published by American Chemical Society (ACS) in ChemRxiv
Open AccessAJICAP Second Generation: Improved Chemical Site-Specific Conjugation Technology for Antibody-Drug Conjugate Production
The site-directed chemical conjugation of antibodies remains an area of great interest and active efforts within the antibody-drug conjugate (ADC) community. We previously reported a unique site modification using a class of immunoglobulin-G (IgG) Fc-affinity reagents to establish a versatile, streamlined, and site-selective conjugation of native antibodies to enhance the therapeutic index of the resultant ADCs. This methodology, termed “AJICAP,” successfully modified Lys248 of native antibodies to produce site-specific ADC with a wider therapeutic index than the Food and Drug Administration-approved ADC, Kadcyla. However, the long reaction sequences, including the reduction-oxidation (redox) treatment, increased. In this manuscript, we aimed to present an updated Fc-affinity-mediated site-specific conjugation technology named “AJICAP second generation” without redox treatment utilizing a "one-pot” antibody modification reaction. The stability of Fc affinity reagents was improved owing to structural optimization, enabling the production of various ADCs without aggregation. In addition to Lys248 conjugation, Lys288 conjugated ADCs with homogenous drug-to-antibody ratio of 2 were produced using this technology after a proper modification of the spacer linkage of Fc-affinity peptide reagents. These two conjugation technologies were used to produce over 20 ADCs from several combinations of antibodies and drug linkers. The in vivo profile of Lys248 and Lys288 conjugated ADCs was also compared. Furthermore, non-traditional ADC applications, such as antibody-protein conjugates and antibody-oligonucleotide conjugates, were performed. These results strongly indicate that this Fc affinity conjugation approach is a promising strategy for manufacturing site-specific antibody conjugates.